Join to View Full Profile
925 Gessner RdSte 200Houston, TX 77024
Phone+1 713-827-9525
Fax+1 713-468-3561
Dr. Rakkhit is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Ronjay Rakkhit, based in Houston, TX, is an oncologist with expertise in hematologic conditions such as amyloidosis, hematologic oncology, thrombocytopenia, myelodysplasia, and myelofibrosis. He completed his medical education in 2003 at the Medical University of South Carolina, followed by an internal medicine residency at Baylor College of Medicine and a fellowship in hematology and medical oncology at the University of Texas Health Science Center and M D Anderson Cancer Center. His research includes significant publications on topics like BCR-JAK2 fusion in myeloproliferative diseases and HER2-positive breast cancer, with his work being cited 338 times. Dr. Rakkhit is recognized as a Regional Top Doctor by Castle Connolly in 2014.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Baylor College of MedicineResidency, Internal Medicine, 2003 - 2006
Medical University of South CarolinaClass of 2003
Certifications & Licensure
TX State Medical License 2006 - 2028
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification OncoEMR by Flatiron Health, Flatiron Health, Inc., 2013-2017
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2013-2017
- CMS Meaningful Use Stage 2 Certification OncoEMR, Flatiron Health, Inc., 2013-2017
Publications & Presentations
PubMed
- 352 citationsHigh risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.Ana M. Gonzalez-Angulo, Jennifer K. Litton, Kristine Broglio, Funda Meric-Bernstam, Ronjay Rakkhit
Journal of Clinical Oncology. 2009-12-01
Authored Content
- BCR-JAK2 fusion as a result of a translocation (9;22)(p24;q11.2) in a patient with CML-like myeloproliferative diseaseJanuary 2012
- High risk of recurrence for patients with Her2 positive breast cancers 1 cm or smallerDecember 2009
Press Mentions
New Legal Risk for Oncologists? Stark Law Fears Loom Ahead of DeadlineMay 8th, 2023
Other Languages
- Spanish, Bengali
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
